APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Vaccine

Compare research editions
View pricing & licenses

Selected research

Industry Research

Peptide Vaccine Industry Research Report 2026

29 December 2025132 pages

Choose your research edition.

Industry ResearchPeptide Vaccine Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Vaccine Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Peptide Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Vaccine Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Vaccine Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Peptide Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Peptide Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Peptide Vaccine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Peptide Vaccine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Peptide Vaccine include Anergis, Antigen Express, Apitope Technology, Artificial Cell Technologies, Benovus Bio, Celgene Corporation, Immatics biotechnologies, ImmunoCellular Therapeutics and ISA Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Peptide Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Peptide Vaccine Market by Company

Anergis

Antigen Express

Apitope Technology

Artificial Cell Technologies

Benovus Bio

Celgene Corporation

Immatics biotechnologies

ImmunoCellular Therapeutics

ISA Pharmaceuticals

Lytix Biopharma

OncoTherapy Science

Peptech

Pharmasyntez

Spotlight Innovation

Sumitomo Dainippon Pharma

TapImmune

Targovax

Merck

Peptide Vaccine Segment by Type

Solution Phase Synthesis (SPS)

Solid Phase Peptide Synthesis (SPPS)

Peptide Vaccine Segment by Application

Pancreatic Cancer

Gastric Cancer

Breast Cancer

Prostate Cancer

Lung Cancer

Others

Peptide Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Peptide Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Peptide Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Peptide Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Peptide Vaccine Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Peptide Vaccine Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Peptide Vaccine Sales Market Share by Manufacturers (2021-2026) Table 8. Global Peptide Vaccine Revenue of Manufacturers (2021-2026) Table 9. Global Peptide Vaccine Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Peptide Vaccine Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Peptide Vaccine Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Peptide Vaccine, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Peptide Vaccine, Product Type & Application Table 14. Global Peptide Vaccine Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Peptide Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Anergis Company Information Table 19. Anergis Business Overview Table 20. Anergis Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Anergis Peptide Vaccine Product Portfolio Table 22. Anergis Recent Developments Table 23. Antigen Express Company Information Table 24. Antigen Express Business Overview Table 25. Antigen Express Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Antigen Express Peptide Vaccine Product Portfolio Table 27. Antigen Express Recent Developments Table 28. Apitope Technology Company Information Table 29. Apitope Technology Business Overview Table 30. Apitope Technology Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Apitope Technology Peptide Vaccine Product Portfolio Table 32. Apitope Technology Recent Developments Table 33. Artificial Cell Technologies Company Information Table 34. Artificial Cell Technologies Business Overview Table 35. Artificial Cell Technologies Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Artificial Cell Technologies Peptide Vaccine Product Portfolio Table 37. Artificial Cell Technologies Recent Developments Table 38. Benovus Bio Company Information Table 39. Benovus Bio Business Overview Table 40. Benovus Bio Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Benovus Bio Peptide Vaccine Product Portfolio Table 42. Benovus Bio Recent Developments Table 43. Celgene Corporation Company Information Table 44. Celgene Corporation Business Overview Table 45. Celgene Corporation Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Celgene Corporation Peptide Vaccine Product Portfolio Table 47. Celgene Corporation Recent Developments Table 48. Immatics biotechnologies Company Information Table 49. Immatics biotechnologies Business Overview Table 50. Immatics biotechnologies Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Immatics biotechnologies Peptide Vaccine Product Portfolio Table 52. Immatics biotechnologies Recent Developments Table 53. ImmunoCellular Therapeutics Company Information Table 54. ImmunoCellular Therapeutics Business Overview Table 55. ImmunoCellular Therapeutics Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. ImmunoCellular Therapeutics Peptide Vaccine Product Portfolio Table 57. ImmunoCellular Therapeutics Recent Developments Table 58. ISA Pharmaceuticals Company Information Table 59. ISA Pharmaceuticals Business Overview Table 60. ISA Pharmaceuticals Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. ISA Pharmaceuticals Peptide Vaccine Product Portfolio Table 62. ISA Pharmaceuticals Recent Developments Table 63. Lytix Biopharma Company Information Table 64. Lytix Biopharma Business Overview Table 65. Lytix Biopharma Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Lytix Biopharma Peptide Vaccine Product Portfolio Table 67. Lytix Biopharma Recent Developments Table 68. OncoTherapy Science Company Information Table 69. OncoTherapy Science Business Overview Table 70. OncoTherapy Science Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. OncoTherapy Science Peptide Vaccine Product Portfolio Table 72. OncoTherapy Science Recent Developments Table 73. Peptech Company Information Table 74. Peptech Business Overview Table 75. Peptech Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Peptech Peptide Vaccine Product Portfolio Table 77. Peptech Recent Developments Table 78. Pharmasyntez Company Information Table 79. Pharmasyntez Business Overview Table 80. Pharmasyntez Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Pharmasyntez Peptide Vaccine Product Portfolio Table 82. Pharmasyntez Recent Developments Table 83. Spotlight Innovation Company Information Table 84. Spotlight Innovation Business Overview Table 85. Spotlight Innovation Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Spotlight Innovation Peptide Vaccine Product Portfolio Table 87. Spotlight Innovation Recent Developments Table 88. Sumitomo Dainippon Pharma Company Information Table 89. Sumitomo Dainippon Pharma Business Overview Table 90. Sumitomo Dainippon Pharma Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Sumitomo Dainippon Pharma Peptide Vaccine Product Portfolio Table 92. Sumitomo Dainippon Pharma Recent Developments Table 93. TapImmune Company Information Table 94. TapImmune Business Overview Table 95. TapImmune Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. TapImmune Peptide Vaccine Product Portfolio Table 97. TapImmune Recent Developments Table 98. Targovax Company Information Table 99. Targovax Business Overview Table 100. Targovax Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Targovax Peptide Vaccine Product Portfolio Table 102. Targovax Recent Developments Table 103. Merck Company Information Table 104. Merck Business Overview Table 105. Merck Peptide Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Merck Peptide Vaccine Product Portfolio Table 107. Merck Recent Developments Table 108. Global Peptide Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 109. Global Peptide Vaccine Sales by Region (2021-2026) & (K Units) Table 110. Global Peptide Vaccine Sales Market Share by Region (2021-2026) Table 111. Global Peptide Vaccine Sales by Region (2027-2032) & (K Units) Table 112. Global Peptide Vaccine Sales Market Share by Region (2027-2032) Table 113. Global Peptide Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 114. Global Peptide Vaccine Revenue Market Share by Region (2021-2026) Table 115. Global Peptide Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 116. Global Peptide Vaccine Revenue Market Share by Region (2027-2032) Table 117. North America Peptide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. North America Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 119. North America Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 120. North America Peptide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 121. North America Peptide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 122. Europe Peptide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Europe Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 124. Europe Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 125. Europe Peptide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 126. Europe Peptide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 127. Asia Pacific Peptide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Asia Pacific Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 129. Asia Pacific Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 130. Asia Pacific Peptide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 131. Asia Pacific Peptide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 132. South America Peptide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. South America Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 134. South America Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 135. South America Peptide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 136. South America Peptide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 137. Middle East and Africa Peptide Vaccine Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Middle East and Africa Peptide Vaccine Sales by Country (2021-2026) & (K Units) Table 139. Middle East and Africa Peptide Vaccine Sales by Country (2027-2032) & (K Units) Table 140. Middle East and Africa Peptide Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 141. Middle East and Africa Peptide Vaccine Revenue by Country (2027-2032) & (US$ Million) Table 142. Global Peptide Vaccine Sales by Type (2021-2026) & (K Units) Table 143. Global Peptide Vaccine Sales by Type (2027-2032) & (K Units) Table 144. Global Peptide Vaccine Sales Market Share by Type (2021-2026) Table 145. Global Peptide Vaccine Sales Market Share by Type (2027-2032) Table 146. Global Peptide Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 147. Global Peptide Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 148. Global Peptide Vaccine Revenue Market Share by Type (2021-2026) Table 149. Global Peptide Vaccine Revenue Market Share by Type (2027-2032) Table 150. Global Peptide Vaccine Price by Type (2021-2026) & (US$/Unit) Table 151. Global Peptide Vaccine Price by Type (2027-2032) & (US$/Unit) Table 152. Global Peptide Vaccine Sales by Application (2021-2026) & (K Units) Table 153. Global Peptide Vaccine Sales by Application (2027-2032) & (K Units) Table 154. Global Peptide Vaccine Sales Market Share by Application (2021-2026) Table 155. Global Peptide Vaccine Sales Market Share by Application (2027-2032) Table 156. Global Peptide Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 157. Global Peptide Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 158. Global Peptide Vaccine Revenue Market Share by Application (2021-2026) Table 159. Global Peptide Vaccine Revenue Market Share by Application (2027-2032) Table 160. Global Peptide Vaccine Price by Application (2021-2026) & (US$/Unit) Table 161. Global Peptide Vaccine Price by Application (2027-2032) & (US$/Unit) Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Peptide Vaccine Distributors List Table 165. Peptide Vaccine Customers List Table 166. Peptide Vaccine Industry Trends Table 167. Peptide Vaccine Industry Drivers Table 168. Peptide Vaccine Industry Restraints Table 169. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Peptide Vaccine Product Image Figure 5. Global Peptide Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Peptide Vaccine Market Size (2021-2032) & (US$ Million) Figure 7. Global Peptide Vaccine Sales (2021-2032) & (K Units) Figure 8. Global Peptide Vaccine Average Price (US$/Unit) & (2021-2032) Figure 9. Solution Phase Synthesis (SPS) Product Image Figure 10. Solid Phase Peptide Synthesis (SPPS) Product Image Figure 11. Pancreatic Cancer Product Image Figure 12. Gastric Cancer Product Image Figure 13. Breast Cancer Product Image Figure 14. Prostate Cancer Product Image Figure 15. Lung Cancer Product Image Figure 16. Others Product Image Figure 17. Global Peptide Vaccine Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of Peptide Vaccine, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 Peptide Vaccine Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Peptide Vaccine Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global Peptide Vaccine Sales by Region in 2025 Figure 23. Global Peptide Vaccine Revenue by Region in 2025 Figure 24. North America Peptide Vaccine Market Size by Country in 2025 Figure 25. North America Peptide Vaccine Sales Market Share by Country (2021-2032) Figure 26. North America Peptide Vaccine Revenue Market Share by Country (2021-2032) Figure 27. United States Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Europe Peptide Vaccine Market Size by Country in 2025 Figure 30. Europe Peptide Vaccine Sales Market Share by Country (2021-2032) Figure 31. Europe Peptide Vaccine Revenue Market Share by Country (2021-2032) Figure 32. Germany Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. France Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. U.K. Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Italy Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Asia Pacific Peptide Vaccine Market Size by Country in 2025 Figure 38. Asia Pacific Peptide Vaccine Sales Market Share by Country (2021-2032) Figure 39. Asia Pacific Peptide Vaccine Revenue Market Share by Country (2021-2032) Figure 40. China Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Japan Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. South Korea Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. India Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Australia Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. China Taiwan Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Southeast Asia Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South America Peptide Vaccine Market Size by Country in 2025 Figure 49. South America Peptide Vaccine Sales Market Share by Country (2021-2032) Figure 50. South America Peptide Vaccine Revenue Market Share by Country (2021-2032) Figure 51. Mexico Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Brazil Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Argentina Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Middle East and Africa Peptide Vaccine Market Size by Country in 2025 Figure 55. Middle East and Africa Peptide Vaccine Sales Market Share by Country (2021-2032) Figure 56. Middle East and Africa Peptide Vaccine Revenue Market Share by Country (2021-2032) Figure 57. Turkey Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. UAE Peptide Vaccine Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Global Peptide Vaccine Sales Market Share by Type (2021-2032) Figure 61. Global Peptide Vaccine Revenue Market Share by Type (2021-2032) Figure 62. Global Peptide Vaccine Price (US$/Unit) by Type (2021-2032) Figure 63. Global Peptide Vaccine Sales Market Share by Application (2021-2032) Figure 64. Global Peptide Vaccine Revenue Market Share by Application (2021-2032) Figure 65. Global Peptide Vaccine Price (US$/Unit) by Application (2021-2032) Figure 66. Peptide Vaccine Value Chain Figure 67. Peptide Vaccine Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Peptide Vaccine Industry Opportunities and Challenges

Scope & coverage.

Types
  • Solution Phase Synthesis (SPS)
  • Solid Phase Peptide Synthesis (SPPS)
Applications
  • Pancreatic Cancer
  • Gastric Cancer
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Others
Companies covered
  • Anergis
  • Antigen Express
  • Apitope Technology
  • Artificial Cell Technologies
  • Benovus Bio
  • Celgene Corporation
  • Immatics biotechnologies
  • ImmunoCellular Therapeutics
  • ISA Pharmaceuticals
  • Lytix Biopharma
  • OncoTherapy Science
  • Peptech
  • Pharmasyntez
  • Spotlight Innovation
  • Sumitomo Dainippon Pharma
  • TapImmune
  • Targovax
  • Merck

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Peptide Vaccine Market Size (2021-2032)
  4. 2.2.2 Global Peptide Vaccine Sales (2021-2032)
  5. 2.2.3 Global Peptide Vaccine Market Average Price (2021-2032)
  6. 2.3 Peptide Vaccine by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Solution Phase Synthesis (SPS)
  9. 2.3.3 Solid Phase Peptide Synthesis (SPPS)
  10. 2.4 Peptide Vaccine by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Pancreatic Cancer
  13. 2.4.3 Gastric Cancer
  14. 2.4.4 Breast Cancer
  15. 2.4.5 Prostate Cancer
  16. 2.4.6 Lung Cancer
  17. 2.4.7 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Peptide Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Peptide Vaccine Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Peptide Vaccine Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Peptide Vaccine Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Peptide Vaccine Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Peptide Vaccine, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Peptide Vaccine, Product Type & Application
  8. 3.8 Global Manufacturers of Peptide Vaccine, Established Date
  9. 3.9 Global Peptide Vaccine Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Anergis
  2. 4.1.1 Anergis Company Information
  3. 4.1.2 Anergis Business Overview
  4. 4.1.3 Anergis Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Anergis Peptide Vaccine Product Portfolio
  6. 4.1.5 Anergis Recent Developments
  7. 4.2 Antigen Express
  8. 4.2.1 Antigen Express Company Information
  9. 4.2.2 Antigen Express Business Overview
  10. 4.2.3 Antigen Express Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Antigen Express Peptide Vaccine Product Portfolio
  12. 4.2.5 Antigen Express Recent Developments
  13. 4.3 Apitope Technology
  14. 4.3.1 Apitope Technology Company Information
  15. 4.3.2 Apitope Technology Business Overview
  16. 4.3.3 Apitope Technology Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Apitope Technology Peptide Vaccine Product Portfolio
  18. 4.3.5 Apitope Technology Recent Developments
  19. 4.4 Artificial Cell Technologies
  20. 4.4.1 Artificial Cell Technologies Company Information
  21. 4.4.2 Artificial Cell Technologies Business Overview
  22. 4.4.3 Artificial Cell Technologies Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Artificial Cell Technologies Peptide Vaccine Product Portfolio
  24. 4.4.5 Artificial Cell Technologies Recent Developments
  25. 4.5 Benovus Bio
  26. 4.5.1 Benovus Bio Company Information
  27. 4.5.2 Benovus Bio Business Overview
  28. 4.5.3 Benovus Bio Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Benovus Bio Peptide Vaccine Product Portfolio
  30. 4.5.5 Benovus Bio Recent Developments
  31. 4.6 Celgene Corporation
  32. 4.6.1 Celgene Corporation Company Information
  33. 4.6.2 Celgene Corporation Business Overview
  34. 4.6.3 Celgene Corporation Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Celgene Corporation Peptide Vaccine Product Portfolio
  36. 4.6.5 Celgene Corporation Recent Developments
  37. 4.7 Immatics biotechnologies
  38. 4.7.1 Immatics biotechnologies Company Information
  39. 4.7.2 Immatics biotechnologies Business Overview
  40. 4.7.3 Immatics biotechnologies Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Immatics biotechnologies Peptide Vaccine Product Portfolio
  42. 4.7.5 Immatics biotechnologies Recent Developments
  43. 4.8 ImmunoCellular Therapeutics
  44. 4.8.1 ImmunoCellular Therapeutics Company Information
  45. 4.8.2 ImmunoCellular Therapeutics Business Overview
  46. 4.8.3 ImmunoCellular Therapeutics Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 ImmunoCellular Therapeutics Peptide Vaccine Product Portfolio
  48. 4.8.5 ImmunoCellular Therapeutics Recent Developments
  49. 4.9 ISA Pharmaceuticals
  50. 4.9.1 ISA Pharmaceuticals Company Information
  51. 4.9.2 ISA Pharmaceuticals Business Overview
  52. 4.9.3 ISA Pharmaceuticals Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 ISA Pharmaceuticals Peptide Vaccine Product Portfolio
  54. 4.9.5 ISA Pharmaceuticals Recent Developments
  55. 4.10 Lytix Biopharma
  56. 4.10.1 Lytix Biopharma Company Information
  57. 4.10.2 Lytix Biopharma Business Overview
  58. 4.10.3 Lytix Biopharma Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Lytix Biopharma Peptide Vaccine Product Portfolio
  60. 4.10.5 Lytix Biopharma Recent Developments
  61. 4.11 OncoTherapy Science
  62. 4.11.1 OncoTherapy Science Company Information
  63. 4.11.2 OncoTherapy Science Business Overview
  64. 4.11.3 OncoTherapy Science Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 OncoTherapy Science Peptide Vaccine Product Portfolio
  66. 4.11.5 OncoTherapy Science Recent Developments
  67. 4.12 Peptech
  68. 4.12.1 Peptech Company Information
  69. 4.12.2 Peptech Business Overview
  70. 4.12.3 Peptech Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Peptech Peptide Vaccine Product Portfolio
  72. 4.12.5 Peptech Recent Developments
  73. 4.13 Pharmasyntez
  74. 4.13.1 Pharmasyntez Company Information
  75. 4.13.2 Pharmasyntez Business Overview
  76. 4.13.3 Pharmasyntez Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Pharmasyntez Peptide Vaccine Product Portfolio
  78. 4.13.5 Pharmasyntez Recent Developments
  79. 4.14 Spotlight Innovation
  80. 4.14.1 Spotlight Innovation Company Information
  81. 4.14.2 Spotlight Innovation Business Overview
  82. 4.14.3 Spotlight Innovation Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Spotlight Innovation Peptide Vaccine Product Portfolio
  84. 4.14.5 Spotlight Innovation Recent Developments
  85. 4.15 Sumitomo Dainippon Pharma
  86. 4.15.1 Sumitomo Dainippon Pharma Company Information
  87. 4.15.2 Sumitomo Dainippon Pharma Business Overview
  88. 4.15.3 Sumitomo Dainippon Pharma Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Sumitomo Dainippon Pharma Peptide Vaccine Product Portfolio
  90. 4.15.5 Sumitomo Dainippon Pharma Recent Developments
  91. 4.16 TapImmune
  92. 4.16.1 TapImmune Company Information
  93. 4.16.2 TapImmune Business Overview
  94. 4.16.3 TapImmune Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 TapImmune Peptide Vaccine Product Portfolio
  96. 4.16.5 TapImmune Recent Developments
  97. 4.17 Targovax
  98. 4.17.1 Targovax Company Information
  99. 4.17.2 Targovax Business Overview
  100. 4.17.3 Targovax Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Targovax Peptide Vaccine Product Portfolio
  102. 4.17.5 Targovax Recent Developments
  103. 4.18 Merck
  104. 4.18.1 Merck Company Information
  105. 4.18.2 Merck Business Overview
  106. 4.18.3 Merck Peptide Vaccine Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Merck Peptide Vaccine Product Portfolio
  108. 4.18.5 Merck Recent Developments
5 Global Peptide Vaccine Market Scenario by Region
  1. 5.1 Global Peptide Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Peptide Vaccine Sales by Region: 2021-2032
  3. 5.2.1 Global Peptide Vaccine Sales by Region: 2021-2026
  4. 5.2.2 Global Peptide Vaccine Sales by Region: 2027-2032
  5. 5.3 Global Peptide Vaccine Revenue by Region: 2021-2032
  6. 5.3.1 Global Peptide Vaccine Revenue by Region: 2021-2026
  7. 5.3.2 Global Peptide Vaccine Revenue by Region: 2027-2032
  8. 5.4 North America Peptide Vaccine Market Facts & Figures by Country
  9. 5.4.1 North America Peptide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Peptide Vaccine Sales by Country (2021-2032)
  11. 5.4.3 North America Peptide Vaccine Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Peptide Vaccine Market Facts & Figures by Country
  15. 5.5.1 Europe Peptide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Peptide Vaccine Sales by Country (2021-2032)
  17. 5.5.3 Europe Peptide Vaccine Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Peptide Vaccine Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Peptide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Peptide Vaccine Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Peptide Vaccine Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Peptide Vaccine Market Facts & Figures by Country
  35. 5.7.1 South America Peptide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Peptide Vaccine Sales by Country (2021-2032)
  37. 5.7.3 South America Peptide Vaccine Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Peptide Vaccine Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Peptide Vaccine Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Peptide Vaccine Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Peptide Vaccine Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Peptide Vaccine Sales by Type (2021-2032)
  2. 6.1.1 Global Peptide Vaccine Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Peptide Vaccine Sales Market Share by Type (2021-2032)
  4. 6.2 Global Peptide Vaccine Revenue by Type (2021-2032)
  5. 6.2.1 Global Peptide Vaccine Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Peptide Vaccine Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Peptide Vaccine Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Peptide Vaccine Sales by Application (2021-2032)
  2. 7.1.1 Global Peptide Vaccine Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Peptide Vaccine Sales Market Share by Application (2021-2032)
  4. 7.2 Global Peptide Vaccine Revenue by Application (2021-2032)
  5. 7.2.1 Global Peptide Vaccine Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Peptide Vaccine Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Peptide Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Peptide Vaccine Value Chain Analysis
  2. 8.1.1 Peptide Vaccine Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Peptide Vaccine Production Mode & Process
  5. 8.2 Peptide Vaccine Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Peptide Vaccine Distributors
  8. 8.2.3 Peptide Vaccine Customers
9 Global Peptide Vaccine Analyzing Market Dynamics
  1. 9.1 Peptide Vaccine Industry Trends
  2. 9.2 Peptide Vaccine Industry Drivers
  3. 9.3 Peptide Vaccine Industry Opportunities and Challenges
  4. 9.4 Peptide Vaccine Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst